BRIEF-Adamas announces FDA acceptance of ADS-5102 new drug application

* Adamas announces FDA acceptance of ADS-5102 new drug application for the treatment of levodopa-induced dyskinesia in patients with parkinson's disease
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.